Approaches towards Antiparasitic Drug Candidates for Veterinary Use

Antiparasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates

Volumn , Issue , 2009, Pages 117-133

  Chassaing, Christophe ^a   Sekljic, Harald ^a  

^a Intervet Innovation GmbH   (Germany)

Author keywords

Antiparasitic; Drug discovery; Infectious diseases; Lead optimization; Veterinary; Workflows

Indexed keywords

EID: 84884101691     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527626816.ch8     Document Type: Chapter

References (53)

1. Mehlhorn, H. (ed.) (2008) Encyclopedia of Parasitology, 3rd edn, Springer, Berlin.
2. Trouiller, P., Olliaro, P., Torreele, E., Orbinski, J., Laing, R. and Ford, N. (2002) Drug development for neglected diseases: a deficient market and a public-health policy failure. The Lancet, 359, 2188-2194.
3. Pink, R., Hudson, A., Mouries, M.-A. and Bendig, M. (2005) Opportunities and challenges in antiparasitic drug discovery. Nature Reviews. Drug Discovery, 4, 727-740.
4. deStevens, G. (1986) Serendipity and structured research in drug discovery. Progress in Drug Research, 30, 189-203.
5. Carleton, E. (1905) Serendipity. The New York Times, April 29, Page BR282.
6. Campbell, W.C. (2005) Serendipity and new drugs for infectious disease. ILAR Journal, 46, 352-356.
7. Fayard, C. (1949) Ascaridiose et piperazine. Thesis for the doctorate in medicine, Faculty of Medicine of Paris.
8. Mann, P.H., Harfenist, M. and deBeer, E.J. (1955) The effectiveness of piperazine citrate against intestinal helminths of the cat and dog. The Journal of Parasitology, 41, 575-578.
9. Mouriquand, G., Roman, E. and Coisnard, J. (1951) Essai de traitement de l'oxyurose par la piperazine. Journal de Medecine de Lyon, 32, 189-195.
10. Seubert, J., Pohlke, R. and Loebich, F. (1977) Synthesis and properties of praziquantel, a novel broad spectrum anthelminthic with excellent activity against Schistosomes and Cestodes. Experientia, 33, 1036-1037.
11. Groll, E. (1984) Praziquantel. Advances in Pharmacology and Chemotherapy, 20, 219-238.
12. Raeymaekers, A.H.M., Allewijn, F.T.N., Vandenberk, J., Demoen, P.J.A., Van Offenwert, T.T.T. and Janssen, P.A.J. (1966) Novel broad-spectrum anthelmintics. Tetramisole and related derivatives of 6-Arylimidazo[2, 1-b]thiazole. Journal of Medicinal Chemistry, 9, 545-551.
13. Geary, T.G., Conder, G.A. and Bishop, B. (2004) The changing landscape of antiparasitic drug discovery for veterinary medicine. Trends in Parasitology, 20, 449-455.
14. Omura, S. and Crump, A. (2004) The lifeandtimes ofivermectin-asuccess story. Nature Reviews Microbiology, 2, 984-989.
15. Kalman, T.I. (1981) Enzyme inhibition as a source of new drugs. Drug Development Research, 1, 311-328.
16. McCarter, J.P. (2004) Genomic filtering: an approach to discovering novel antiparasitics. Trends in Parasitology, 20, 462-468.
17. Geary, T.G., Bowman, J.W., Friedman, A.R., Maule, A.G., Davis, J.P., Winterrowd, C.A., Klein, R.D. and Thompson, D.P. (1995) The pharmacology of FMRFamide-related neuropeptides in nematodes: new opportunities for rational anthelmintic discovery? International Journal for Parasitology, 25, 1273-1280.
18. Foster, J.M., Zhang, Y., Kumar, S. and Carlow, C.K.S. (2005) Mining nematode genome data for novel drug targets. Trends in Parasitology, 21, 101-104.
19. Gilleard, J.S., Woods, D.J. and Dow, J.A.T. (2005) Model-organism genomics in veterinary parasite drug-discovery. Trends in Parasitology, 21, 302-305.
20. Krasky, A., Rohwer, A., Schroeder, J. and Selzer, P.M. (2006) A combined bioinformatics and chemoinformatics approach for the development of new antiparasitic drugs. Genomics, 89, 36-43.
21. Shoop, W.L., Mrozik, H. and Fisher, M.H. (1995) Structure and activity of avermectins and milbemycins in animal health. Veterinary Parasitology, 59, 139-156.
22. Adam, M. (2007) The changing significance of chance experiments in technological development, in Ausgewählte Beitrage zu den Sektionen der GAP. 6 (Berlin, 11.-14. 9. 2006) (eds H. Bohse, K. Dreimann and S. Walter), Mentis, Paderborn.
23. Bren, L. (2000) Prescriptions for healthier animals-humans and animals often take similar drugs. FDA Consumer, 34: November.
24. Petkewich, R. (2007) Big pharma chases dogs and cats. Chemical & Engineering News, 85, 31-34.
25. Fairlamb, A.H., Ridley, R.G. and Vial, H.J. (eds) (2003) Drugs Against Parasitic Diseases: R&D Methodologies and Issues. TDR, World Health Organization, Geneva.
26. Keiser, J. et al. (2007) Supplementary Articles. Expert Opinion on Drug Discovery, 2 (Supp. 1), S1-S103.
27. Keiser, J. and Utzinger, J. (2007) Advances in the discovery and development of trematocidal drugs. Expert Opinion on Drug Discovery, 2 (Supp. 1), S9-S23.
28. Pines, M., Vlodavsky, I. and Nagler, A. (2000) Halofuginone: from veterinary use to human therapy. Drug Development Research, 50, 371-378.
29. Meinke, P.T., Smith, H.M. and Shoop, W.L. (2002) Nodulisporic acid: its chemistry and biology. Current Topics in Medicinal Chemistry, 2, 655-674.
30. Burkhart, C.G. and Burkhart, C.N. (2006) Safety and efficacy of pediculicides for head lice. Expert Opinion on Drug Safety, 5, 169-179.
31. Agrafiotis, D.K. (2001) Multiobjective optimization of combinatorial libraries. IBM Journal of Research and Development, 45, 545-565.
32. Sams-Dodd, F. (2006) Drug discovery: selecting the optimal approach. Drug Discovery Today, 11, 465-472.
33. Witty, M.J. (1999) Current strategies in the search for antiparasitic agents. International Journal for Parasitology, 29, 95-103.
34. Geary, T.G., Thompson, D.P. and Klein, R.D. (1999) Mechanism-based screening: discovery of the next generation of anthelmintic depends upon more basic research. International Journal for Parasitology, 29, 105-112.
35. Geary, T.G. and Thompson, D.P. (2001) Caenorhabditis elegans: how good a model for veterinary parasites? Veterinary Parasitology, 101, 371-386.
36. Griffioen, G. (2007) Targeting disease, not disease targets: Innovative approaches in tackling neurodegenerative disorders. IDrugs, 10, 259-263.
37. Brown, D. (2007) Unfinished business: target-based drug discovery. DrugDiscovery Today, 12, 1007-1012.
38. Butcher, E.C. (2005) Can cell systems biology rescue drug discovery? Nature Reviews. Drug Discovery, 4, 461-467.
39. Thomsen, W., Frazer, J. and Unett, D. (2005) Functional assays for screening GPCR targets. Current Opinion in Biotechnology, 16, 655-665.
40. Geary, T.G., Sangster, N.C. and Thompson, D.P. (1999) Frontiers in anthelmintic pharmacology. Veterinary Parasitology, 84, 275-295.
41. Bennett, J.L. and Pax, R.A. (1987) Micromotility meter: Instrumentation to analyse helminth motility. Parasitology Today, 3, 159-160.
42. Petersen, M.B., Friis, C. and Bjørn, H. (1997) A new in vitro assay of benzimidazole activity against adult Oesophagostomum dentatum. International Journal for Parasitology, 27, 1333-1339;
43. Rapson, E.B., Jenkins, D.C. and Topley, P. (1985) Trichostrongylus colubriformis: In vitro culture of parasitic stages and their use for the evaluation of anthelmintics. Research in Veterinary Science, 39, 90-94;
44. Rew, R.S., Urban, J.F. and Douvres, F.W. (1986) Screen for anthelmintics, using larvae of Ascaris suum. American Journal of Veterinary Research, 47, 869-873;
45. Rothwell, J.T. and Sangster, N.C. (1993) An in vitro assay utilising parasitic larval Haemonchus contortus to detect resistance to closantel and other anthelmintics. International Journal for Parasitology, 23, 573-578.
46. Terstappen, G.C., Schlüpen, C., Raggiaschi, R. and Gaviraghi, G. (2007) Target deconvolution strategies in drug discovery. Nature Reviews. Drug Discovery, 6, 891-903.
47. Alvarez, L.I., Mottier, M.L. and Lanusse, C.E. (2007) Drug transfer into target helminth parasites. Trends in Parasitology, 23, 97-104.
48. Coles, G.C., Jackson, J., Pomroy, W.E., Prichard, R.K., von Samson-Himmelstjerna, G., Silvestre, A., Taylor, M.A. and Vercruysse, J. (2006) The detection of anthelmintic resistance in nematodes of veterinary importance. Veterinary Parasitology, 136, 167-185.
49. Hart, C. (2005) Finding the target after screening the phenotype. Drug Discovery Today, 10, 513-519.
50. Austen, M. and Dohrmann, C. (2005) Phenotype-first screening for the identification of novel drug targets. Drug Discovery Today, 10, 275-282.
51. Marriner, S.E. and Bogan, J.A. (1981) Pharmacokinetics of fenbendazole in sheep. American Journal of Veterinary Research, 42, 1146-1148.
52. Wermuth, C.G. (2006) Similarity in drugs: reflections on analogue design. Drug Discovery Today, 11, 348-354.
53. Lathers, C.M. (2003) Challenges and opportunities in animal drug development: a regulatory perspective. Nature Reviews. Drug Discovery, 2, 1-4.